Literature DB >> 29281002

An automated benchmarking platform for MHC class II binding prediction methods.

Massimo Andreatta1, Thomas Trolle2, Zhen Yan3, Jason A Greenbaum3, Bjoern Peters4, Morten Nielsen1,5.   

Abstract

Motivation: Computational methods for the prediction of peptide-MHC binding have become an integral and essential component for candidate selection in experimental T cell epitope discovery studies. The sheer amount of published prediction methods-and often discordant reports on their performance-poses a considerable quandary to the experimentalist who needs to choose the best tool for their research.
Results: With the goal to provide an unbiased, transparent evaluation of the state-of-the-art in the field, we created an automated platform to benchmark peptide-MHC class II binding prediction tools. The platform evaluates the absolute and relative predictive performance of all participating tools on data newly entered into the Immune Epitope Database (IEDB) before they are made public, thereby providing a frequent, unbiased assessment of available prediction tools. The benchmark runs on a weekly basis, is fully automated, and displays up-to-date results on a publicly accessible website. The initial benchmark described here included six commonly used prediction servers, but other tools are encouraged to join with a simple sign-up procedure. Performance evaluation on 59 data sets composed of over 10 000 binding affinity measurements suggested that NetMHCIIpan is currently the most accurate tool, followed by NN-align and the IEDB consensus method. Availability and implementation: Weekly reports on the participating methods can be found online at: http://tools.iedb.org/auto_bench/mhcii/weekly/. Contact: mniel@bioinformatics.dtu.dk. Supplementary information: Supplementary data are available at Bioinformatics online.

Mesh:

Substances:

Year:  2018        PMID: 29281002      PMCID: PMC5925780          DOI: 10.1093/bioinformatics/btx820

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


  24 in total

1.  Towards the in silico identification of class II restricted T-cell epitopes: a partial least squares iterative self-consistent algorithm for affinity prediction.

Authors:  I A Doytchinova; D R Flower
Journal:  Bioinformatics       Date:  2003-11-22       Impact factor: 6.937

2.  Automated benchmarking of peptide-MHC class I binding predictions.

Authors:  Thomas Trolle; Imir G Metushi; Jason A Greenbaum; Yohan Kim; John Sidney; Ole Lund; Alessandro Sette; Bjoern Peters; Morten Nielsen
Journal:  Bioinformatics       Date:  2015-02-25       Impact factor: 6.937

Review 3.  Pathways of antigen processing.

Authors:  Janice S Blum; Pamela A Wearsch; Peter Cresswell
Journal:  Annu Rev Immunol       Date:  2013-01-03       Impact factor: 28.527

4.  SVRMHC prediction server for MHC-binding peptides.

Authors:  Ji Wan; Wen Liu; Qiqi Xu; Yongliang Ren; Darren R Flower; Tongbin Li
Journal:  BMC Bioinformatics       Date:  2006-10-23       Impact factor: 3.169

5.  Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A.

Authors:  Ronit Mazor; Chin-Hsien Tai; Byungkook Lee; Ira Pastan
Journal:  J Immunol Methods       Date:  2015-06-06       Impact factor: 2.287

6.  Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research.

Authors:  Hong Huang Lin; Guang Lan Zhang; Songsak Tongchusak; Ellis L Reinherz; Vladimir Brusic
Journal:  BMC Bioinformatics       Date:  2008-12-12       Impact factor: 3.169

7.  Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method.

Authors:  Morten Nielsen; Claus Lundegaard; Ole Lund
Journal:  BMC Bioinformatics       Date:  2007-07-04       Impact factor: 3.169

8.  Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries.

Authors:  John Sidney; Erika Assarsson; Carrie Moore; Sandy Ngo; Clemencia Pinilla; Alessandro Sette; Bjoern Peters
Journal:  Immunome Res       Date:  2008-01-25

9.  The immune epitope database (IEDB) 3.0.

Authors:  Randi Vita; James A Overton; Jason A Greenbaum; Julia Ponomarenko; Jason D Clark; Jason R Cantrell; Daniel K Wheeler; Joseph L Gabbard; Deborah Hix; Alessandro Sette; Bjoern Peters
Journal:  Nucleic Acids Res       Date:  2014-10-09       Impact factor: 16.971

10.  Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High Specificity.

Authors:  Geert P M Mommen; Fabio Marino; Hugo D Meiring; Martien C M Poelen; Jacqueline A M van Gaans-van den Brink; Shabaz Mohammed; Albert J R Heck; Cécile A C M van Els
Journal:  Mol Cell Proteomics       Date:  2016-01-13       Impact factor: 5.911

View more
  25 in total

1.  Improved peptide-MHC class II interaction prediction through integration of eluted ligand and peptide affinity data.

Authors:  Christian Garde; Sri H Ramarathinam; Emma C Jappe; Morten Nielsen; Jens V Kringelum; Thomas Trolle; Anthony W Purcell
Journal:  Immunogenetics       Date:  2019-06-10       Impact factor: 2.846

2.  Bioinformatic Techniques for Vaccine Development: Epitope Prediction and Structural Vaccinology.

Authors:  Peter McCaffrey
Journal:  Methods Mol Biol       Date:  2022

3.  Immunoinformatic Design of a Multivalent Peptide Vaccine Against Mucormycosis: Targeting FTR1 Protein of Major Causative Fungi.

Authors:  Yusha Araf; Abu Tayab Moin; Vladimir I Timofeev; Nairita Ahsan Faruqui; Syeda Afra Saiara; Nafisa Ahmed; Md Sorwer Alam Parvez; Tanjim Ishraq Rahaman; Bishajit Sarkar; Md Asad Ullah; Mohammad Jakir Hosen; Chunfu Zheng
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

4.  DeepMHCII: a novel binding core-aware deep interaction model for accurate MHC-II peptide binding affinity prediction.

Authors:  Ronghui You; Wei Qu; Hiroshi Mamitsuka; Shanfeng Zhu
Journal:  Bioinformatics       Date:  2022-06-24       Impact factor: 6.931

5.  Evolutionary Pressure against MHC Class II Binding Cancer Mutations.

Authors:  Rachel Marty Pyke; Wesley Kurt Thompson; Rany M Salem; Joan Font-Burgada; Maurizio Zanetti; Hannah Carter
Journal:  Cell       Date:  2018-09-20       Impact factor: 41.582

6.  Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes.

Authors:  Julien Racle; Justine Michaux; Georg Alexander Rockinger; Marion Arnaud; Sara Bobisse; Chloe Chong; Philippe Guillaume; George Coukos; Alexandre Harari; Camilla Jandus; Michal Bassani-Sternberg; David Gfeller
Journal:  Nat Biotechnol       Date:  2019-10-14       Impact factor: 54.908

Review 7.  Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.

Authors:  Rahul Khetan; Robin Curtis; Charlotte M Deane; Johannes Thorling Hadsund; Uddipan Kar; Konrad Krawczyk; Daisuke Kuroda; Sarah A Robinson; Pietro Sormanni; Kouhei Tsumoto; Jim Warwicker; Andrew C R Martin
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

8.  Unbiased Characterization of Peptide-HLA Class II Interactions Based on Large-Scale Peptide Microarrays; Assessment of the Impact on HLA Class II Ligand and Epitope Prediction.

Authors:  Mareike Wendorff; Heli M Garcia Alvarez; Thomas Østerbye; Hesham ElAbd; Elisa Rosati; Frauke Degenhardt; Søren Buus; Andre Franke; Morten Nielsen
Journal:  Front Immunol       Date:  2020-08-05       Impact factor: 7.561

9.  Improved prediction of HLA antigen presentation hotspots: Applications for immunogenicity risk assessment of therapeutic proteins.

Authors:  Anders Steenholdt Attermann; Carolina Barra; Birkir Reynisson; Heidi Schiøler Schultz; Ulrike Leurs; Kasper Lamberth; Morten Nielsen
Journal:  Immunology       Date:  2020-10-19       Impact factor: 7.397

10.  Peptide presentation by HLA-DQ molecules is associated with the development of immune tolerance.

Authors:  Máté Manczinger; Lajos Kemény
Journal:  PeerJ       Date:  2018-07-03       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.